Our second item of business is consideration of PE1463, on effective thyroid and adrenal testing, diagnosis and treatment. We will take evidence from the Minister for Public Health, who is accompanied by four officials. We are also joined by Elaine Smith MSP, who has taken a keen interest in the petition. We will allow her an opportunity to join our discussion. I welcome the minister and her officials and invite the minister to make a short statement, after which we will move to questions.
Official Report · Committee
Continued Petitions
Thyroid and Adrenal Testing and Treatment (PE1463)
Speakers
Choose an MSP to read only their contributions- Professor Leese 38
- Michael McMahon Lab 26
- Maureen Watt SNP 19
- Jackson Carlaw Con 19
- Elaine Smith Lab 10
- Hanzala Malik Lab 6
- Angus MacDonald SNP 5
- John Wilson Ind 3
- David Torrance SNP 2
- Alpana Mair Scottish Government 2
- Professor Graham Leese NHS Tayside and Chief Medical Officer Specialty Adviser 1
The record
131 contributionsGood morning and thank you for inviting me to give evidence. At the outset, I make it clear that I have not only an on-going interest in the petition as Minister for Public Health but a personal interest, as I have previously made public. I was substituting at the Public Petitions Committee in 2013 when the petition was discussed.
I am aware that many people are affected by thyroid problems and that some of them have been unwell for some time, having experienced difficulties in obtaining diagnosis and appropriate treatment. I am sympathetic to the challenges that they face. First and foremost, I stress that we take the petition and what the petitioners are saying very seriously.
Although I have an understanding of the issues that will be raised today, I recognise that the committee may ask questions of a more clinical nature, so I may require to refer some questions to Professor Graham Leese, who is the chief medical officer’s specialty adviser on diabetes and endocrinology and is also an honorary professor in diabetes and endocrinology at the University of Dundee.
As the committee is aware, the Scottish Government commissioned a listening exercise to be carried out by Thyroid UK on the experiences of hypothyroid patients. An online survey was carried out during the summer of 2015 across the whole United Kingdom. Respondents were invited to complete the survey from a variety of sources, including the Thyroid UK website, a forum, Facebook and Twitter. There were approximately 5,000 respondents to the survey and just over 4,000 surveys were fully completed.
The purpose of the listening exercise was to obtain a comprehensive picture of what was happening in patients’ experiences of diagnosis and treatment. The survey was aimed at patients who have been diagnosed with hypothyroidism, as well as those who have symptoms of hypothyroidism but have not yet been diagnosed. A number of questions were asked to cover patient experience, diagnosis, treatment and general practitioner knowledge. The results of the survey are available on Thyroid UK’s website and I take the opportunity to thank the charity for carrying out that useful work in helping us to obtain a better understanding of patients’ condition, diagnosis, treatment and experience.
Committee members will be well aware that the Scottish Government’s role is to provide policies, frameworks and resources to national health service boards to allow them to deliver services that meet the needs of their local populations. In that context, the provision of healthcare services is the responsibility of local boards, which take into account national guidance, local service needs and priorities for investment.
It should be recognised that progress in clinical science has been, and should continue to be, based on properly conducted, scientifically based trials that strive to eliminate any error or unrecognised confounding issues. It is appreciated that progress can sometimes be frustratingly slow, but that is the consequence of trying to get things right and ensure patient safety, which is paramount at all times. Anecdote and clinical observation can be useful to raise scientific questions, but such questions need to be tested rigorously; otherwise, the approach can be potentially detrimental and dangerous to patients, as well as wasteful of NHS resources, not just for thyroid disease but for all other medical conditions.
The position statement by the British Thyroid Association, which was published in May 2015, clearly sets out its recommendations on the management of primary hypothyroidism on the basis of the current literature and a review of the published positions of the European Thyroid Association and the American Thyroid Association, and it is in line with best principles for medical practice. The recommendations have been endorsed by the Association for Clinical Biochemistry and Laboratory Medicine, the British Thyroid Foundation, the Royal College of Physicians and the Society for Endocrinology, and they therefore reflect current best practice in the management of primary hypothyroidism, about which Professor Leese will be able to speak more if needed.
The British Thyroid Foundation is a patient support group that has worked since 1991 with medical professional bodies, such as those that I just mentioned, to provide guidance for all patients—and their relatives—who have thyroid disease, including those with underactive thyroid, overactive thyroid, thyroid cancer and thyroid eye disease. The foundation has endorsed the British Thyroid Association guidelines. In addition, the foundation has written a frequently asked questions sheet for patients and published it on its website. Guidance that has been written for GPs is expected to be published later this year in a GP-oriented medical journal.
I am aware that the petitioner has met representatives of the Scottish intercollegiate guidelines network and that an outcome of that discussion is that the SIGN council hopes to determine, in conjunction with the Royal College of Physicians, whether it may be helpful to produce a good practice guide on the topic for general practitioners. Ultimately, that will be a decision for the SIGN council, and the Scottish Government cannot influence that decision, although I welcome SIGN’s consideration of the proposal.
Thank you—that was a comprehensive overview of the situation from your perspective. As you said, the petition has been running for a substantial time. Committee members have gained an in-depth understanding of the matter as the petition has gone forward and I know that some of them are keen to ask questions to follow up the work that has been done. I invite the deputy convener, David Torrance, to ask the first set of questions.
link
The Thyroid UK survey report shows that 42 per cent of respondents considered that their clinician was not open to discussion about treatment options and that more than 50 per cent considered that their GP’s knowledge of hypothyroidism was poor. How does the Government react to those findings and what recommendations will it put in place?
As I said, the survey was UK wide, so we cannot extrapolate the Scottish situation from it. It did not involve a randomised sample, as one would normally expect in, say, a clinical trial. The people who responded are very involved in the issue and the figures quoted are likely to be an overestimation of the situation. GPs and endocrinologists generally follow evidence-based diagnostic guidelines, which are agreed in the specialist community.
As I said, the Government cannot intervene directly, but SIGN is proposing to develop a good practice guide for general practice. Professor Leese is involved in that and can say more.
I am not directly involved with that, but we have been involved with the British Thyroid Association. As the minister mentioned, the British Thyroid Foundation, which is the patient group, has developed a number of responses to frequently asked questions, which will be useful for patients and GPs. In response to what is happening, a number of steps have been taken to increase awareness of such issues among general practitioners and specialists.
Elaine Smith has a question—is it a supplementary on this specific point?
My question is relevant to the point. I might have asked it later, but it is perhaps better if I ask it now, if you do not mind.
We will take your question now, then I will come back to David Torrance.
The petitioner has told me that the British Thyroid Foundation changed its advice online as recently as this week. My question is directly for Professor Leese, if you do not mind, minister. The foundation is now saying that it would be okay for some people to try T3, and I would like to know your opinion on that. It is obviously okay to try it, but a person has to be referred to an endocrinologist by their general practitioner first—GPs will not prescribe T3.
Secondly, it is now being said that it is okay for T4 to be slightly over. That is now acceptable.
Finally, it is being said that whatever medication someone is taking should resolve their symptoms. That brings up the whole issue of desiccated thyroid hormone, which may be prescribed on a named-patient basis, although very few GPs will prescribe it.
I would like to hear comments on those points, please.
I cannot comment on the British Thyroid Foundation document that you refer to, as I am not sure that I have seen it. However, it probably refers to the British Thyroid Association guidelines, which suggest—this is nothing new—that the blood tests are not the whole picture. Placing someone on thyroxine involves a balance between treating symptoms and treating the blood tests. The blood tests give a range that a person should be within in terms of safety. Within that, the dose of thyroxine can be moved around, as long as the figures are kept within the safe range. That is perhaps more explicit in the document, but that has always been the case.
On the use of T3 or liothyronine, there is scope in the British Thyroid Association document that was published in May 2015 for the use of liothyronine in exceptional circumstances. That is also stated in the European and American guidelines—it can be used if, in exceptional circumstances, it is felt that it will benefit the patient. As you said, a referral to an endocrinologist might be needed.
Will you also comment on the range? The committee has been looking into it. It is different in different countries. We have heard evidence that, far too often, general practitioners rely just on the blood tests and do not look at the patient’s symptoms. There are a lot of patients who are on many other medications for various symptoms but, if their thyroid was treated correctly, they would not have to be on all those other medications, which include drugs for depression, drugs for fibromyalgia, painkillers and so on.
If there was better treatment for thyroid patients—treatment that was more centred on them, in the same way as with diabetic patients—there could be moves forward for patients and for the NHS. There is scope for the NHS to save money. Why is care for people with diabetes, which is a fellow endocrine neighbour of hypothyroidism, provided on a person-centred basis, whereas those with underactive thyroid are simply put on levothyroxine? There is one medicine for them.
The evidence suggests that patients who are on thyroxine are treated very much at an individual level. The guidelines, and most GPs, try to adapt the levels according to the symptoms, as long as they are within the safe range according to the blood tests.
I say, perhaps for people who are not so involved in the issue, that anybody who is on levothyroxine gets tested. They get a thyroid-stimulating hormone—TSH—blood test every year. If there are abnormalities in that test, they are tested for T4. If there are still abnormalities, there may be a test for T3. That is my understanding. Routinely, patients who are on levothyroxine get an annual blood test to see whether there have been any changes. The dosage may be increased, or it may be reduced, according to what the blood tests show.
10:15
It is worth noting that there is a wide range of what is deemed to be acceptable TSH, so there is scope for moving doses, perhaps to small amounts, to maintain patients within the wide range of TSH that is thought to be safe.
link
The minister said that new guidelines for GPs would be published later in the year. Will you expand a bit on what is in the guidelines and how quickly SIGN will implement them?
There needs to be increased general awareness of the guidelines. That comes down to educating GPs and advertising the guidelines. Each year, every GP must do a certain amount of professional development, so there are opportunities to educate GPs. They have a huge number of areas to cover, but thyroid disease could be included in that training.
The condition is something that most GPs will come across in their practice.
Just as Diabetes UK’s website includes information on tests for people with diabetes and what they should be getting from their GPs, there are websites, including the British Thyroid Foundation’s website, that people who take levothyroxine should be aware of. Patients’ awareness of such websites is important.
I accept what the minister said about the figures in the survey report being UK based, which means that the true picture in Scotland is not clear. Perhaps she will consider doing a report of her own to determine the figures in Scotland.
Making doctors aware is important. I am not getting a sense of the timescales by which you intend to circulate the information for GPs so that they are equipped with the information and the support that they need.
The guidelines, which have been available since May, are not a one-off. As with any advertising campaign, it comes down to continuing to promote them—to increase awareness, we have to keep at it. We must keep educating GPs in the philosophy of treating patients within a range of TSH, along with the need to perhaps change doses. The information is not new; it is simply re-emphasised in the guidelines.
You are stepping around the issue and you are still not giving me a clear guide on how you are focusing on it. How will we assess the success of the advertising campaign? Surely you will be looking for facts and figures on that. What are the timescales in which you are looking to achieve the outcomes? I seek further clarity on how quickly you hope to deliver on the ground.
There are already SIGN guidelines for GPs. We are talking about whether there will perhaps be revised SIGN guidelines.
One of the petitioners has been involved in seeing whether the current—and any future—SIGN guidelines should be altered. As a result of discussions, it was discovered that the current guidelines are pretty good and that, if things had been left to the petitioner, she would probably have come up with more or less what is out there now. Interruption.
I ask for order in the public gallery, please. I ask the minister to stop for a moment while the matter is dealt with. Interruption. I am sorry for the disturbance, minister. Please carry on.
As I said, my understanding is that the petitioner was involved in discussions about SIGN guidelines—I do not know whether anyone else wants to come in on that—and that the Royal College of Physicians will issue new ones through the SIGN council in the near future.
I accept what you say and I am sure that you will try to ensure that the guidelines are fit for purpose, but I have been pressing you on the matter—I will stop after this, which is my third attempt. I am looking for some sort of timeframe for when you hope to achieve that because, without a timeframe, the process will be open ended, which is surely unhelpful.
As I said in my opening statement, the timing is not up to the Scottish Government. It is up to the SIGN council—we cannot really determine its timeframe.
The guidelines are being distributed at the moment. You talked about measuring their success, Mr Malik, and I would welcome your thoughts as to how we do that.
Shall I respond to that, convener?
If you are being asked a question, you can respond if you have an answer.
I am happy to do that in a bid to help. I have already indicated that we do not have Scottish figures.
Figures for what?
For how many patients there are, how many benefit from the service, how much information is available to GPs and whether the service is being delivered successfully. At the end of the day, this has to be measured. Everything must be measurable. If it is not measurable, we cannot judge its success or failure and we do not know whether we need to change things or leave the status quo.
I would like to know that as well. Hanzala Malik is making a good point that you have not clarified. We are relying on the Thyroid UK survey—
Can I answer the points that have been made?
I am just enhancing the question, if you do not mind. If I make a point, you can respond. I am not stopping you from responding. I just want to add to what my colleague said because I want clarity as well.
You are relying on Thyroid UK’s survey, which has evidence that people have been refused T3 treatment. You accept the survey and that there are issues in it. The question that is being asked—or the question that I would like to add to the one that has been asked—is: given that we do not have a full picture in Scotland and that you are dependent on a survey that you consider not to be complete, why are we not trying to complete the picture? You are working on the basis of a survey that does not give you the answers but, from what I can see, you are not doing anything to find the answers. Why not?
First, we know exactly how many patients are on thyroxine in Scotland. We also know how many are on liothyronine.
Do you know how many have been denied treatments for which they have asked?
No, we do not. We do not know that from the Thyroid UK survey either.
That is the point that I am making. We do not know that from the survey, but you are not telling us how you will try to find it out.
There are about 6,500 prescriptions in Scotland for T3. That involves 1 per cent of people who are on thyroid medication. However, there is no evidence to support the routine use of thyroid extracts—the T3 monotherapy or the compound thyroid hormone. You are giving the wrong impression that a patient can just ask for T3 and routinely be put on it. That is not the same—
With all due respect, minister, I am not giving any impression. I am asking why, if all the work that we are discussing and all our understanding of the situation is based primarily on a report that you consider to be incomplete, you are not trying to complete the understanding of the situation.
We did not say that the survey was incomplete. We undertook to do a listening exercise and we commissioned Thyroid UK to undertake it. It did that across the whole UK.
We know from that survey what patients think about their treatment, and as a result the specialists have taken forward the SIGN guidelines.
Convener—
I will let you in again later, Elaine. I know that you have a lot of questions, and I will not let you miss the opportunity to ask them, but some of your colleagues have been waiting for some time now. Angus MacDonald will go next.
Minister, you mentioned that there are currently 6,500 patients on T3. We know that there have been supply issues with the medication in recent months. As Mercury Pharma is the only licensed manufacturer of T3 in the UK, there is clearly an issue with its monopoly on supply.
In light of those supply issues, is the Government aware of any action that has been taken to evaluate improvements to Mercury Pharma’s process for manufacturing T3 tablets? Is it likely that another UK manufacturer of T3 will come forward in the near future, which would assist with the supply? Is the number of people on T3 limited to 6,500 because of the supply issues? Could more people be given T3 if more of it was available?
There have previously been supply issues with T3, and action has been taken to evaluate the improvements to Mercury Pharma’s process for manufacturing the tablets. However, as members will know, regulation of supply is reserved to the UK Government and enforcement of the regulations on supply is a matter for the Medicines and Healthcare products Regulatory Authority. We are not aware of any issues with the supply of T3 tablets at present. The chief pharmacist may want to come in at this point.
For clarification, we know that the number of prescriptions dispensed for T3 is 6,500 at present. Our Scottish officials are in regular contact with colleagues in the Department of Health, who will work with the manufacturers on improving their processes to ensure that there is continuity of supply for patients and that we do not experience the same problems that arose a couple of years back. Work has been undertaken to try to resolve some of those issues, and there were no supply issues at all in 2015.
As for Mercury Pharma being the only company that produces the drug, that is a commercial decision for a company to make. The number of T3 prescriptions is small in comparison with the 2.5 million T4 prescriptions, and it would be a company, not the UK Government, that would decide to produce the medication. As I have said, there were no supply issues in 2015, and active steps have been taken to improve the manufacturing process to ensure continuity of supply for patients.
The other part of my question was about whether you were aware of any other manufacturers who might be looking at producing the medication. Of course, you might not be.
We are not aware of that from our colleagues. A company will make a commercial decision about whether to manufacture the drug.
My next question might be a bit naive. The current issue with natural desiccated thyroid is that personal liability lies with the prescriber or the GP, and the onus is on them if there is any comeback. Would a solution be to approve the product and allow it to be used without any comeback on the GP? The current situation might be one of the reasons that very few people are currently prescribed natural desiccated thyroid; in fact, I believe that people are even buying it off the internet because of the current issues.
10:30
There are some physicians who prescribe liothyronine, because it has a licence, but there is no robust clinical evidence of its benefit, and significant theoretical concerns have been raised about its long-term safety.
Out in the wide world, there is evidence that it works.
I think that the professor would say that that evidence is anecdotal, but I will hand over to him.
I am sure that the patients would vouch for the fact that it works.
I will put a few of the issues together to try and get clarity.
Everyone would agree that there are patients on thyroxine who do not feel well. That is recognised by everyone in the profession, and it is highlighted in the Thyroid UK survey. The issue is not so much the number of people or whatever but what we can do about it. As has been said, it all comes down to anecdote versus clinical evidence. The original statement said that 11 out of 12 trials showed no benefit from liothyronine for patients feeling unwell on thyroxine, and one randomised control trial with desiccated thyroid showed no benefit.
That said, there are anecdotal reports and, as a professional group, we try to listen to those anecdotal reports and take them forward in a scientific way. That is what happened with the randomised control trials, but when they have been carried out in a controlled clinical environment, they did not support the use of those other agents.
That is where we are at at the moment, but that will not stop us doing more clinical trials and perhaps trying to look at specific patient groups that might benefit from those drugs. All the guidelines that I have mentioned are evidence based, because that is the way that clinical practice works.
The guidance advises that patients who remain symptomatic should be referred to an endocrinologist for further investigation, but some people who live with hypothyroidism or thyroid problems will see that that is not happening. However, the committee held an evidence session with SIGN in November 2014 and agreed to invite SIGN to consider developing further guidance and guidelines as a result.
I have a couple of questions about the work of Thyroid UK and the survey that was produced. We know from the preface—and from the minister, who also mentioned this—that it was the Scottish Government that commissioned the research. How much did it cost?
I do not have a figure for that, but we can get it to you.
When the research was commissioned, was Thyroid UK given no guidance on including the extrapolation of Scottish patient experience in the survey? The minister and Professor Leese have both said that the experience of patients in Scotland cannot be extrapolated from the report, because the Scottish Government commissioned the report without asking specifically for the details of Scottish patients’ experience. The petition is asking the committee to deal with the experience of Scottish patients. I hope that the minister provides the committee with details of the cost of the piece of work that was commissioned from Thyroid UK, but there is also a clear issue here with regard to who commissioned the work and why it did not focus on Scottish patients’ experience of their treatment and the existing diagnosis regime in Scotland.
I hope that Thyroid UK will be able to take the report to the UK Government and make a good case for better treatment regimes in the UK and in England and Wales, but this committee is concentrating on the experience of patients in Scotland, and it would have been extremely useful if whoever had drawn up the commissioning document had asked Thyroid UK to break the information down and give us Scottish figures in relation to the areas that have been identified. Clearly, that never happened. I hope that the minister can come back to us with not only the cost of the research but the reason why she did not specifically ask in the commissioned piece of work for information on the treatment and diagnosis experience of Scottish patients in relation to the petition that we are dealing with.
Let us go back a step. I think that some people were under the impression that a short-life working group would be set up, but my predecessor advised the committee in a letter dated 5 February 2014 that there was no evidence base to support the changes that were being sought by the petition at that time.
Instead, we asked Thyroid UK to carry out a listening exercise, which resulted in the survey that it undertook. As I have said previously, the survey was conducted through the Thyroid UK website, Facebook and Twitter. It was not a survey in the sense that a specific group of people were asked questions; that was not what the exercise was meant to do in the first place. We can certainly send you details of the cost.
My colleague has just said to me, “Why not?” in relation to the exercise and the situation that we are looking at. We heard earlier about the petitioner’s frustration with some of the minister’s responses about decisions that have been made since the committee received the petition in 2012, and we as a committee will examine that matter further.
However, with regard to the Scottish Government’s decision to commission a piece of work to identify the issues, you mentioned a listening group. How do you establish a Scottish listening group if what you do is take examples from the rest of the UK? We are trying to deal with examples of Scottish patient experience. We know that across the UK there might be different experiences in different health boards where different guidance has been issued. You have mentioned the SIGN guidance that will be issued, but the fact is that you cannot instruct SIGN on how to give that guidance. Clearly, though, the Scottish Government has a role to play in that matter.
The point is that the committee asked the Scottish Government to examine the patient experience, the medication that is being provided to patients and its benefits, and you have spent money—we do not know how much yet, but we hope to get the figure—asking an organisation to conduct a survey that, quite frankly, was not worth the money that was spent on it. I am paraphrasing what you have said about it. It gives us nothing conclusive that will allow us to try to take forward the issues that have been raised in the petition.
I am not aware of the parameters for the listening exercise that was undertaken. I have said that I will write to the committee about how much the research cost and what the parameters were. However, I doubt that the experience of patients across the UK will be all that different in relation to the issues at hand. Given the state of the health service south of the border, it might actually be worse there.
Like one or two colleagues, I have been following the petition since it was launched in 2012, and I know that the aim of the petitioner was to give endocrinologists the ability to diagnose thyroid and adrenal disorders accurately and provide the most appropriate treatment. That was where we began.
Professor Leese, your words are very carefully couched, but I have to say that you seem to be branding the solutions that patients are looking for as nothing more than quackery. However, thousands of women are clearly not benefiting or are being made unwell from the routinely prescribed treatment of T4 in Scotland.
You have said that the evidence is only anecdotal. I would love to hear a definition of “anecdotal”, because it could mean a little woman at the bus stop who said that she read something in the Daily Express or Hello! magazine or the first-hand experience of thousands of women who, after being prescribed with one of these solutions, have said that the allergic reactions or symptoms that they previously had have been alleviated and that they are now well.
I do not want to call it professional conceit, but it almost seems that there was a predetermined establishment position in a survey that was meant to be part of a listening exercise, but which now seems to have been the listening exercise, and which I understand involved multiple patient groups with diseases, not just the one that we are looking at. I was a little astonished by this, but I think that the minister said at one point that those who responded to the survey were very involved in it, which might explain why it was weighted as it was. What would have been the point of the survey if it did not involve people who were very involved in it? Naturally, I would expect that to be the outcome.
It seems to me that, after three and a half years, there is an establishment position. I have heard that in relation to other things, and nobody wants people to be prescribed things that are unsafe, but let us look at this charge of anecdotal evidence. You talked about clinical trials. Where and when were they conducted? How many people were involved in them? What is the real substance in the face of what is not trivial evidence to us as politicians, but the real-life experience of many women, which seems to me to direct that there ought to be a process by which we try to do more by way of prescribing alternatives?
You are giving the impression that you think that there is a conspiracy theory behind all this. In reality, I think that if you speak to any clinician—or 99 per cent of them—they will—
Where does that 99 per cent come from? That is like my saying 99 per cent of the Parliament.
If 6,500 people are being prescribed, doctors are clearly making decisions to give particular women the medication, so how can you come up with the figure of 99 per cent of people believing that the survey that you have is the accurate position?
I am sorry, but I do not think that you are listening.
Oh, okay.
I asked you where the 99 per cent came from.
Where did the 99 per cent come from? We have had figures bandied about all morning about the number of people who are being prescribed, and you have just plucked a figure out of the air to justify your position.
Was 99 per cent perhaps an anecdotal percentage?
I said that the majority of clinicians are actually—
That could be 51 per cent, not 99 per cent. It could be closer to 51 per cent.
I am not quite sure what I am being asked and whether anyone is interested in the answer.
I am asking you where your figure of 99 per cent came from.
Of what?
You said that 99 per cent of clinicians agree. Where is that 99 per cent established?
Did I say that? I did not say 99 per cent agree.
You did.
No, I did not.
We will move on. We are not going to agree on the figures, so can we just get the position clarified?
What I was saying or what I was trying to say was that the majority of clinicians—I said perhaps 99 per cent, because there may be the odd one who is not, and I was then interrupted—
Where does that figure come from?
That is just typical.
No. I am asking you where your 99 per cent comes from.
Every time that I try to make the statement, I am interrupted. Can I start again?
No. I am asking you specifically—
Can I finish my statement?
No. You are actually responding to my question.
Jackson—
I am asking you—
I am not even being asked.
—where your 99 per cent figure comes from.
What?
You have said that 99 per cent of clinicians believe. Where is that 99 per cent verified?
No. I never said that 99 per cent of clinicians believe. I said—Interruption. What? Can I please finish the sentence this time, for the third time?
Yes, if you do not mind.
I said that the majority of clinicians are compassionate—that is what I was trying to say—
No, you did not say that.
No. That is because I kept getting interrupted.
No, you did not. I think that it was a good while after you had made your point that Jackson Carlaw asked you to clarify what you were actually trying to say.
10:45
Well, I hope that this is on tape, because that is not—
It is. It is all recorded.
I talked about the majority of clinicians, and I was about to say that there might be the odd one who is not, but 99 per cent of clinicians—this is when I got interrupted, but this is what I was going on to say—will be very compassionate about the problems that patients are facing. That is what I was trying to say and that is what I am trying to get across.
Comments about conspiracy theories and quackery are not fair. The majority of clinicians will be upset when they have patients in front of them who have on-going symptoms, despite being on thyroxine. There are a number of different possible reasons for such symptoms, which I can go into if the committee wants me to do so. The other thing that we need to think about is that clinicians do not want to do any harm with the treatments that they prescribe or recommend.
The other point that I want to get across, in relation to what was said about anecdote, is that anecdotes often raise good clinical questions, which is exactly why we listen to anecdotes. Those questions then need to be tested, as I have said, in a clinical trial, to ensure that a therapy will have benefits.
I can give you an example from a completely different disease area: painful neuropathy. We do trials in which we give drugs for pain. That involves giving half the patients in the trial the active drug and half the patients a placebo drug; it is a blinded study, so that people do not know who is getting what. In those kinds of trials, up to 50 per cent of patients will get pain relief from the placebo.
That is why we need to do clinical trials—we need to see whether drugs really do benefit people or whether there are other aspects of the care that help patients. That is why I come back to the compassion that clinicians want to show—and in the majority of cases do show—to their patients.
Those are the points that I wanted to get across. I am sorry if I got mixed up in all that.
Let me pursue your point about clinical trials. Where were they conducted? When were they conducted? How many women were involved?
I cannot tell you the exact number. Thousands of patients were involved in the trials—
Is this an anecdotal response?
No, it is just my—
You do not know—that is the answer. Perhaps you could write to the committee, giving us full details of the clinical trials. I do not want to know what you think; I want to know what you know. When were they conducted? How many women were involved?
I said that I do not know the exact numbers involved. The trials were conducted between 1999 and 2008—I think that that was the last one—and thousands of patients were involved. One trial showed a benefit but the other 11 randomised controlled trials did not show a benefit. There have been four meta-analyses undertaken—
Where were the trials conducted?
Across the western world; in America and in the United Kingdom. The four meta-analyses that combined the trials did not show a benefit.
Are you going to forward that information to us?
I can do that.
May I answer Mr Carlaw’s question about the listening exercise? We have to remember that hundreds of thousands of people who have thyroid problems and who are probably on thyroxine live perfectly healthy lives. In relation to the listening exercise, we said that the people who were most motivated to respond to the questions that Thyroid UK posed were likely to be those who were most unwell and most unhappy with the service that they were getting from their clinicians. We are trying to establish the best way to take forward the concerns of the patients who are still feeling unwell and who are suffering from thyroid problems but might be suffering from other problems.
Elaine Smith is right—most clinicians look at the whole person. The drugs that a person needs might not necessarily be related to their thyroid problem. I accept that totally. I hope that such issues will be highlighted to GPs in the guidelines and through the various thyroid organisations. That will help patients in the appointments and discussions that they have with their GPs and—if they are passed on to secondary care—with the endocrinologists.
I really do not know where to start. If the minister thinks that I said that most clinicians look at the whole person, that is a mistake. I said that GPs tend to look at blood test results and not at the whole person. Dr Anthony Toft made the point that medical professionals should not just look at the blood results but should look at the patient, listen to their symptoms and work out from there what they should be doing. That is one issue. Another issue is the other drugs that people are on. Often, people are on those drugs because of their thyroid problems. If they were on the right medication for their thyroid, they might not have to be on antidepressants, pain medications and so on.
Obviously, the petitioner was rather upset by what the minister said earlier. Perhaps the minister was wrongly briefed, because, as I understand it, the petitioner did not come to any agreement about guidelines. In fact, she is not aware that there are guidelines for thyroid conditions. Like me, she is interested—I do not know whether the committee would be interested as well—in getting a copy of the guidelines that are in existence at the moment. I think that it would be interesting for everybody to see them.
Yes.
The next issue is whether the minister is confident that the current treatment for hypothyroidism can be considered safe when it is admitted that 10 per cent of patients remain unwell on levothyroxine. Personally, I think that the figure is a lot higher. The professor talked about people on T4 never coming back and saying that they are unwell, but I know lots of people who feel unwell but do not think that it is related to their thyroid because they are told, “Here’s this little pill. Take it for the rest of your life and you’ll be absolutely fine. We’ll test you once a year to see how your bloods are.”
It is not routine to test T4, and it is certainly not routine to test T3. What can you say to the 10 per cent—which is a modest estimate—who are not doing well? What are we going to do for them? What can we say to the people who are not being diagnosed because they are slightly outwith the ranges? If they were in America, they would be getting diagnosed. What do we say to all the people in this country—we do not even know how many of them there are—who are buying desiccated thyroid hormone off the internet? Why was desiccated thyroid hormone fine until a pharmaceutical company invented T4? Those questions about how patients are going to be treated in the future really have to be answered.
I do not think that I, as a politician, should say what the medical profession should do. That is up to the medical profession. However, I make it clear that there is guidance for patients and for GPs and endocrinologists at the moment. There are no SIGN guidelines but there is guidance, and SIGN guidelines are being developed, as Professor Leese said. There is a difference between guidance and guidelines. I will let Professor Leese answer your other questions.
There were a lot of questions, and I hope that a lot of the answers may be within the British Thyroid Association guidelines, which are very similar to the European and American ones. You are shaking your head, Ms Smith—you do not think so.
I am afraid not. I do not know how you will feel about this—it is anecdotal, as you would put it. You said earlier that people could go back to their GP if they were unwell. The problem is that lots of people—mainly women but some men—go back when they are unwell and are told a list of different things. I have been through this myself, which is why my evidence is anecdotal. First, you are told, “It sounds like depression—here are some antidepressants.” You are then told, “Oh, it’s probably your weight. Let’s see if you can go on a diet.” Next, you are told, “Oh, we can give you co-codamol for your fibromyalgia,” and so it goes on. It never comes back to the fact that the problem is your thyroid.
For me, that process went on for two years. In those two years, I had brain scans and blood tests, and I was tested for Lyme disease—I was tested for lots of things. I was also put on heart monitors. It must have cost a fortune. That was because, instead of being sent to an endo, I was sent to a neurologist. I did not have an endo at that point. I was eventually told that I had ME, but I did not accept that. Even though I was ill, I was quite assertive and demanded that my GP send me to Dr Anthony Toft. After one session with Dr Toft, a blood test showed that I was not converting T4 to T3. I was put on T3 and, six weeks later, I was much better although it has taken until now to get the dosage of T3 right.
That is happening to a lot of people. I know women on T4 who tell me about all those other symptoms and say, “I’m all right on my thyroxine—my T4,” but they are not. All those other symptoms are down to the fact that they are not on the right dosage or the fact that they should be on T3 or desiccated thyroid hormone, which was the previous treatment for a lot of people and was considered safe at that time.
Women—and, I suppose, the petition—are looking for patients to be listened to and for GPs to use the named-patient basis to prescribe what is best for the patient so that patients can try out what they want to try out without having to buy things off the internet, which is extremely dangerous. How do you feel about that? You talk about trials, but there are many people whom you will not reach because they are not in the group that you will examine.
With regard to your personal case, there is provision for what you went through. The modern guidelines address your issues, although the previous ones might not have done. Now, in an ideal setting, someone would go down the line that you eventually went down.
I understand that around 20 per cent of people—that figure is, perhaps, anecdotal but I do not have the figures before me—have been diagnosed with ME but have an underlying thyroid condition. Do you think that those people should be tested to see whether they are not converting T4 to T3?
If they were not converting T4 to T3, their TSH would go up.
TSH is not the be-all and end-all. The minister said earlier that GPs can test T3 and T4, but they do not do that routinely. My TSH—I am going into all the details now—is not at a level that anyone other than the endocrinologist who has been dealing with me for years would let it be at. Nevertheless, I am doing well on the T3 that has been upped and the T4 that has been taken down. It is not my TSH blood tests that are being looked at but me and how I am dealing with it.
That is good.
I do not think that we are going to get any further by pursuing that line of questioning. We have given the issue a good airing. I suggest that, because we have received a lot of information and a lot of questions have arisen from that, we need to write to the minister to get some clarification of those points so that we can discuss the matter at a future meeting. We are beginning to run out of time in which to have meetings before the dissolution of Parliament. However, given the questions that have arisen from the evidence this morning, there is still some distance to go with the petition and we must pursue the matter diligently.
We are pressed for time. Our clerks and the Scottish Government officials can discuss the timescale for getting answers, but we need to get them reasonably quickly. I do not think that we will have time to invite the minister back. Perhaps our legacy paper can suggest that we need to keep an eye on the petition given the number of questions that keep arising and the failure to reach a conclusion. I know that everyone came here this morning to be as helpful as possible, but I think that we ended up with more questions than answers. Despite the best of intentions, the information that we received just led to more questions being posed by the committee.
I will not comment on the style of the evidence-taking evidence, but there be might be some dissatisfaction will that, too. If we were to get the answers in a written form, that might help us to make progress. We did not get exactly what we were looking for, which leaves us disappointed, but we must continue to pursue the petition.
Elaine, do you have a suggestion?
11:00
There was some misunderstanding about the difference between the guidelines and the guidance from endocrinologists and others. Sometimes, it is better to get things in writing. Given that the petitioner has been pursuing the matter for nearly four years, I wonder whether she could be afforded an opportunity to come back and give evidence on the information that you have received.
It would be difficult to suggest such a course of action to a future committee. We will have to wait and see, but that option is always on the table. Further consideration of the petition is certainly merited—I think that we can guarantee that—but it would not be for me to tell a future committee whom it should and should not invite to give evidence. That would not be appropriate. We can continue the petition and suggest in our legacy paper that further work needs to be done on it.
As I said, if we can get written answers to the questions that arose this morning so that we can consider the petition further in this Parliament, that will help us, in drafting our legacy paper, to direct the future committee to continue to look at the matter.
I undertake to answer those questions as soon as we can after we get them.
Thank you very much, minister. I also thank your team for coming before us this morning.
I suspend the meeting for a few minutes to allow a changeover of witnesses.
11:01 Meeting suspended.
11:05 On resuming—
In this meeting
Everything on 9 Feb 2016 →- 10:00 Decision on Taking Business in Private Procedure · 1
- 10:00 Continued Petitions Petitions · 131
- 11:00 Continued Petitions Petitions · 99
- 11:45 Continued Petitions Petitions · 20
- 12:15 Continued Petitions Petitions · 1
- 12:15 Continued Petitions Petitions · 3
- 12:15 Continued Petitions Petitions · 35
- 12:15 Continued Petitions Petitions · 5
- 12:15 Continued Petitions Petitions · 5
- 12:45 Continued Petitions Petitions · 7
- 12:45 Continued Petitions Petitions · 4
- 12:45 Continued Petitions Petitions · 1
- 12:45 Continued Petitions Petitions · 9
- 12:45 Continued Petitions Petitions · 6
- 12:45 Continued Petitions Petitions · 1
- 12:45 Continued Petitions Petitions · 4
The type of each item (debate, statement, questions, members’ business and so on) and the times shown are worked out by this site from headings, the chair’s opening words and the Official Report’s running timestamps. They are not the Parliament’s own classification. Text: the Scottish Parliament Official Report.